Biogen Inc. (BIIB)

Income Statement

Difficulty: Beginner

Annual Data

Quarterly Data

The income statement presents information on the financial results of a company's business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.

Biogen Inc., Consolidated Income Statement

USD $ in thousands

	12 months ended	Dec 31, 2017		Dec 31, 2016		Dec 31, 2015		Dec 31, 2014		Dec 31, 2013
	Product, net
	Revenues from anti-CD20 therapeutic programs
	Other
	Revenues
	Cost of sales, excluding amortization of acquired intangible assets
	Gross profit
	Research and development
	Selling, general and administrative
	Amortization of acquired intangible assets
	Acquired in-process research and development
	Collaboration profit sharing
	Gain (loss) on fair value remeasurement of contingent consideration
	Restructuring charges
	TECFIDERA litigation settlement charges
	Gain on sale of rights
	Income from operations
	Interest income
	Interest expense
	Impairments on investments
	Gain (loss) on investments, net
	Foreign exchange gains (losses), net
	Other, net
	Other income (expense), net
	Income before income tax expense and equity in loss of investee, net of tax
	Income tax expense
	Equity in loss of investee, net of tax
	Net income
	Net (income) loss attributable to noncontrolling interests, net of tax
	Net income attributable to Biogen Inc.

Source: Biogen Inc., Annual Reports

Item	Description	The company
Revenues	Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains.	Biogen Inc.'s revenues increased from 2015 to 2016 and from 2016 to 2017.
Income from operations	The net result for the period of deducting operating expenses from operating revenues.	Biogen Inc.'s income from operations increased from 2015 to 2016 and from 2016 to 2017.
Income before income tax expense and equity in loss of investee, net of tax	Sum of operating profit and nonoperating income (expense) before income (loss) from equity method investments, income taxes, extraordinary items, cumulative effects of changes in accounting principles, and noncontrolling interest.	Biogen Inc.'s income before income tax expense and equity in loss of investee, net of tax increased from 2015 to 2016 and from 2016 to 2017.
Net income	The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.	Biogen Inc.'s net income increased from 2015 to 2016 but then declined significantly from 2016 to 2017.
Net income attributable to Biogen Inc.	The portion of consolidated profit or loss for the period, net of income taxes, which is attributable to the parent. If the entity does not present consolidated financial statements, the amount of profit or loss for the period, net of income taxes.	Biogen Inc.'s net income attributable to Biogen Inc. increased from 2015 to 2016 but then declined significantly from 2016 to 2017.

	Biogen Inc.	Other companies (not purchased previously)
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality

	All companies
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality